Cogentis Therapeutics

[On Demand]

We are developing a platform to transform dementia and related neurodegenerative diseases. Our lead therapeutic, CT-526, has reversed Alzheimer's disease in multiple animal models by targeting a previously "undruggable"; target called CDK5. We are continuing to develop it in collaboration with scientists at NIH and Johns Hopkins. Our companion diagnostic can "biopsy" brain tissue with a blood test and stratify patients for therapy as well as monitor target engagement in clinical trials. This noninvasive technique will enhance the entire field of neurological therapeutics. We are currently de-risking our platform for early partnership with Pharma.


Cogentis Therapeutics is presenting as part of the NIH Innovation Zone.

Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Company HQ Country:
United States
Year Founded:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Cogentis Therapeutics